February 23, 2021
1 min read
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact firstname.lastname@example.org.
Back to Healio
Klisyri, a topical treatment for actinic keratosis, has been launched by Almirall following a December approval by the FDA, according to a press release.
Klisyri (tirbanibulin), a novel topical microtubule inhibitor, is indicated for AK treatment on the face and scalp.
In two phase 3 clinical studies, Klisyri achieved significantly higher rates of complete AK clearance compared with vehicle and met its secondary endpoint of partial skin clearance compared with vehicle.
“The incidence of actinic keratosis has been increasing, including in younger adults,” Ayman Grada, MD, head of R&D and medical affairs at Almirall U.S., said in the release. “Patients may prefer a treatment option with a short duration and proven safety and tolerability profile…